Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Illumina

Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.

Benzinga

PacBio (Still) Lags on This Crucial Metric

The genomics company PacBio isn't making much progress in the most important source of revenue.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

First synthetic embryos: the scientific breakthrough raises serious ethical questions

Children, even some who are too young for school, know you can’t make a baby without sperm and an egg. But a team of researchers in Israel have called into question the basics of what we teach children about the birds and the bees, and created a mouse embryo using…

The Conversation

Check Out What Whales Are Doing With Illumina

Benzinga

10x Genomics Stock Rebound Depends on Growth

The formerly high-flying growth stock is stalling against macroeconomic headwinds. How quickly can the business get back on track?

The Street

Tech firms face more regulation after moves to stop 'killer' acquisitions – but innovation could also be under threat

One way to eliminate the competition in business is simply to buy them out and shut them down. And that means less choice for consumers and sometimes the loss of innovative and, in the case of the pharmaceutical industry, even life-saving products. But such so-called killer acquisitions are likely to…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Biden’s FTC has blocked 4 hospital mergers and is poised to thwart more consolidation attempts

Fresh off the Federal Trade Commission’s successful challenges to four hospital mergers, the Biden administration’s new majority on the commission is primed to more aggressively combat consolidation in the health care industry than it has in past years.

Tribune News Service

From Illumina to Twist Bioscience, a Strong Dollar Is Bad News

Wall Street hasn't fully digested what currency devaluation really means for biotech stocks.

The Street

Illumina Whale Trades Spotted

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

Upgrades

Benzinga

Illumina Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 11 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Illumina Stock In The Last 15 Years

Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 9.39% on an annualized basis producing an average annual return of 15.68%. Currently, Illumina has a market capitalization of $29.25 billion.

Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 10 years by 6.06% on an annualized basis producing an average annual return of 16.76%. Currently, Illumina has a market capitalization of $30.53 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

A Beaten-Down Biotech Stock That's Finally Attractive

This lab-hardware business is growing, cashed up, and close to profitability.

Benzinga

If You Invested $100 In Illumina 15 Years Ago, Here's How Much You Would Have Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 11.83% on an annualized basis producing an average annual return of 18.76%. Currently, Illumina has a market capitalization of $36.40 billion.

Benzinga

Why Illumina Shares Are Plunging Today?

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ:ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by Illumina, namely, U.S.…

Benzinga

Where Illumina Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Illumina (NASDAQ:ILMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Pares Losses As Nasdaq Falls 1.4%; Jobs Report Offers Mixed Signals

The Russell 2000 dropped to the lowest level since December 2020.

Benzinga

If You Invested $1000 In Ilumina 10 Years Ago, Here's How Much You Would Have Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 10 years by 7.06% on an annualized basis producing an average annual return of 18.79%. Currently, Illumina has a market capitalization of $39.64 billion.

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Investors Business Daily

DNA Giant Illumina Smashes Profit Views, Though Sales Just Meet

Illumina crushed earnings forecasts on Thursday, though the next-generation DNA sequencer just met sales views. Illumina stock was unchanged.

Benzinga

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Benzinga

Here's How Much You Would Have Made Owning Illumina Stock In The Last 5 Years

Illumina (NASDAQ:ILMN) has outperformed the market over the past 5 years by 1.75% on an annualized basis producing an average annual return of 15.45%. Currently, Illumina has a market capitalization of $56.36 billion.

Benzinga

Analyst Ratings For Illumina

Illumina (NASDAQ:ILMN) has observed the following analyst ratings within the last quarter:

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.